Segment Reporting

9 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

Segment Reporting

12. Segment reporting:

The Company operates in a single industry engaging in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. Accordingly, the Company’s business is classified as a single reportable segment.

The following table presents net sales by product (in thousands):

	Three months ended September 30,				Nine months ended September 30,
	2017		2016		2017		2016
BELBUCA®	$	6,437	$	—	$	17,554	$	—
BUNAVAIL®		1,681		2,009		6,244		6,221
Net product sales	$	8,118	$	2,009	$	23,798	$	6,221